Lassila & Tikanoja plc will publish Financial Statements for 2022 on 9 February 2023
Lassila & Tikanoja plc
Investor News
24 January 2023 10.00 am
Lassila & Tikanoja plc will publish Financial Statements for 2022 on 9 February 2023
Lassila & Tikanoja plc will publish Financial Statements for 2022 on Thursday 9 February 2023 at 8.00 am. After publication, the release will be available on the company's website at www.lt.fi/en.
Lassila & Tikanoja will host a conference call and webcast for analysts, institutional investors and media on 9 February 2023 at 10.30 am Finnish time. The presentation material will be published on the company's website.
The English language briefing will be hosted by CEO Eero Hautaniemi and CFO Valtteri Palin.
Conference call:
You can access the teleconference by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. http://palvelu.flik.fi/teleconference/?id=10010541
Webcast:
To access the audio webcast go to https://lassila-tikanoja.videosync.fi/2022-financial-statements-release
LASSILA & TIKANOJA PLC
Eero Hautaniemi
President and CEO
For additional information please contact
Eero Hautaniemi, President and CEO, tel. +358 10 636 2810
Valtteri Palin, CFO, tel. +358 40 734 7749
Lassila & Tikanoja is a service company that makes circular economy a reality. Together with our customers, we keep materials, properties and factories in productive use for as long as possible and we enhance the use of raw materials and energy. We help our customers maintain the value of their properties and materials while protecting the environment. We achieve this by delivering responsible and sustainable service solutions that make the daily lives of our customers easier. With operations in Finland and Sweden, L&T employs 8,100 people. Net sales in 2021 amounted to EUR 812.5 million. L&T is listed on Nasdaq Helsinki.
Distribution:
Nasdaq Helsinki
Major media
www.lt.fi/en
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Calibre Announces Closing of C$115 Million Financing16.4.2024 14:41:32 CEST | Press release
Not for distribution to U.S. news wire services or dissemination in the United States. VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Calibre Mining Corp. (TSX: CXB; OTCQX: CXBMF) (“Calibre” or the “Company”) is pleased to announce that it has closed its previously announced bought deal financing (the “Offering”) for aggregate gross proceeds of C$115,147,200. Pursuant to the Offering, a total of 68,540,000 common shares of the Company (“Common Shares”), including 8,940,000 Common Shares issued pursuant to the exercise in full of the over-allotment option, were sold at a price of C$1.68 per Common Share. The Common Shares issued pursuant to the Offering were offered by way of a short form prospectus filed in all provinces and territories of Canada, except Québec. The Offering was conducted through a syndicate of underwriters comprised of BMO Capital Markets, as lead underwriter, and Canaccord Genuity Corp., Scotia Capital Inc., Haywood Securities Inc. and Cormark Securi
KALLELSE TILL ÅRSSTÄMMA I CORLINE BIOMEDICAL AB (PUBL)16.4.2024 14:40:36 CEST | Pressemelding
Aktieägarna i Corline Biomedical AB (publ), org.nr 556417-0743 ("Bolaget"), kallas härmed till årsstämma onsdagen den 15 maj 2024 klockan 14.00 i Advokatfirman Lindahls lokaler på Vaksalagatan 10 i Uppsala. Anmälan m.m. Aktieägare som önskar delta i årsstämman måste: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken måndagen den 6 maj 2024,dels anmäla sitt deltagande så att anmälan är Bolaget till handa senast måndagen den 13 maj 2024 (den s.k. avstämningsdagen). Anmälan kan göras via e-post till olle.sward.brattstrom@lindahl.se eller per post till adressen Advokatfirman Lindahl KB, att. Olle Swärd Brattström, Box 1203, 751 42 Uppsala. Vid anmälan uppges aktieägarens namn, person- eller organisationsnummer (eller motsvarande) och gärna adress, telefonnummer, aktieinnehav, uppgift om eventuella biträden (högst två), samt i förekommande fall uppgift om ställföreträdare eller ombud. Förvaltarregistrerade aktier Aktieägare som låtit
Resolutions of Marimekko Corporation’s Annual General Meeting and the Board of Directors’ constitutive meeting16.4.2024 14:40:00 CEST | Press release
Marimekko Corporation, Stock Exchange Release 16 April 2024 at 3.40 p.m. Resolutions of Marimekko Corporation’s Annual General Meeting and the Board of Directors’ constitutive meeting At Marimekko Corporation’s Annual General Meeting (the AGM), held today, and at the subsequent constitutive meeting of the Board of Directors, the following resolutions were passed. A. RESOLUTIONS OF THE ANNUAL GENERAL MEETING Adoption of the financial statements Marimekko Corporation’s income statement and balance sheet and the consolidated income statement and balance sheet for 2023 were adopted. Payment of dividend The AGM approved the Board of Directors’ proposal to distribute a dividend of EUR 0.37 per share for the financial year 2023. The dividend will be paid on 25 April 2024 to shareholders who are registered on the dividend payout record date of 18 April 2024 in the company’s shareholder register held by Euroclear Finland Ltd on behalf of the Board of Directors of the company. Discharge from lia
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer16.4.2024 14:00:00 CEST | Press release
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer. Dr. Khan will lead Recursion’s research and development, and build its emerging commercial capabilities. She has also been appointed to Recursion’s Board of Directors. “Najat brings a unique blend of leadership in biological, chemical, and medical sciences, data science, and business,” said Chris Gibson, Co-Founder and CEO of Recursion. “More importantly, she has a vision and passion for transforming drug discovery and development that complements ours and she has a strong sense of urgency to accelerate the industry’s f
Prosafe SE: Notice of Annual General Meeting to be held on 7 May 202416.4.2024 14:00:00 CEST | Press release
The Annual General Meeting of Prosafe SE will be held on 7 May 2024 at 08.30 a.m. CEST. The meeting will be held as a virtual meeting only, with no physical attendance for shareholders. Live virtual attendance will take place via Lumi AGM. Shareholders who want to participate online do not need to pre-register but must be logged in before the meeting starts. Link to Lumi AGM: https://dnb.lumiagm.com/192234619 Participants will need to identify themselves using their unique reference number and PIN code assigned by the Norwegian Central Securities Depository (Euronext VPS). Online voting in advance of the meeting is possible. Please go to https://investor.vps.no/gm/logOn.htm?token=b64e150d374ed758a81d29d4df0e2fe7249c6066&validTo=1717655400000&oppdragsId=20240312VPKMVMU0 to cast your vote. The deadline for advance voting and submission of proxies is 3 May 2024 at 08:30 a.m. CEST. Attached the Notice of the Annual General Meeting including proxy forms and the Board of Directors' proposed